Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Macular Degeneration
Interventions
DRUG

Bevasiranib

Trial Locations (23)

10021

LuEsther T. Mertz Retinal Research Center, New York

11563

OCLI, Lynbrook

21204

Retina Specialist, Towson

28210

Southeast Clinical Research, Charlotte

33426

Florida Eye Microsurgical Institute, Inc., Boynton Beach

44107

Retina Associates of Cleveland, Inc., Lakewood

44122

Retina Associates of Cleveland, Beachwood

48073

Associated Retinal Consultants, P.C., Royal Oak

49525

Vitreo-Retinal Associates PC, Grand Rapids

49546

Associated Retinal Consultants, Grand Rapids

53226

Medical College of Wisconsin Eye Institute, Milwaukee

55435

VitreoRetinal Surgery, P.A., Edina

57701

Black Hills Eye Institute, Rapid City

64108

Eye Foundation of Kansas City, UMKC School of Medicine, Kansas City

76102

Ophthalmology Associates, Fort Worth

77030

Vitreoretinal Consultants Houston TX, Houston

78705

Retina Reseach Center, Austin

85014

Acuity Participating Site, Phoenix

85704

Retina Centers PC, Tucson

90701

Sall Research Medical Center, Artesia

94598

Bay Area Retina Associates, Walnut Creek

08701

Retina-Vitreous Center, Lakewood

07039

Retina-Vitreous Consultants, Livingston

All Listed Sponsors
lead

OPKO Health, Inc.

INDUSTRY

NCT00259753 - Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter